Trials / Recruiting
RecruitingNCT06130787
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 321 (estimated)
- Sponsor
- University Hospital, Clermont-Ferrand · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Blood and bone marrow sample | Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12. An optional bone marrow sample will be taken during the myelogram performed at diagnosis. Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36 |
Timeline
- Start date
- 2023-11-17
- Primary completion
- 2025-11-17
- Completion
- 2028-11-17
- First posted
- 2023-11-14
- Last updated
- 2024-09-27
Locations
17 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06130787. Inclusion in this directory is not an endorsement.